These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20652729)

  • 1. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.
    Keizer RJ; Gupta A; Mac Gillavry MR; Jansen M; Wanders J; Beijnen JH; Schellens JH; Karlsson MO; Huitema AD
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):347-63. PubMed ID: 20652729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based treatment optimization of a novel VEGFR inhibitor.
    Keizer RJ; Gupta A; Shumaker R; Beijnen JH; Schellens JH; Huitema AD
    Br J Clin Pharmacol; 2012 Aug; 74(2):315-26. PubMed ID: 22295876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.
    Boss DS; Glen H; Beijnen JH; Keesen M; Morrison R; Tait B; Copalu W; Mazur A; Wanders J; O'Brien JP; Schellens JH; Evans TR
    Br J Cancer; 2012 May; 106(10):1598-604. PubMed ID: 22516948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
    Yamada K; Yamamoto N; Yamada Y; Nokihara H; Fujiwara Y; Hirata T; Koizumi F; Nishio K; Koyama N; Tamura T
    Clin Cancer Res; 2011 Apr; 17(8):2528-37. PubMed ID: 21372218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.
    Koyama N; Saito K; Nishioka Y; Yusa W; Yamamoto N; Yamada Y; Nokihara H; Koizumi F; Nishio K; Tamura T
    BMC Cancer; 2014 Jul; 14():530. PubMed ID: 25047123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncontrolled Hypertension and Oncology: Clinical Tips.
    Kalaitzidis RG; Elisaf MS
    Curr Vasc Pharmacol; 2017; 16(1):23-29. PubMed ID: 28413967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.
    Horsley L; Marti K; Jayson GC
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):283-93. PubMed ID: 22283844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts.
    Bruheim S; Kristian A; Uenaka T; Suo Z; Tsuruoka A; Nesland JM; Fodstad Ø
    Int J Cancer; 2011 Aug; 129(3):742-50. PubMed ID: 21225632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.
    Matsui J; Yamamoto Y; Funahashi Y; Tsuruoka A; Watanabe T; Wakabayashi T; Uenaka T; Asada M
    Int J Cancer; 2008 Feb; 122(3):664-71. PubMed ID: 17943726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
    Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J
    Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hypertension in angiogenesis inhibitor-treated patients.
    Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP
    Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.
    Kumar Puttrevu S; Ramakrishna R; Bhateria M; Jain M; Hanif K; Bhatta RS
    Naunyn Schmiedebergs Arch Pharmacol; 2017 May; 390(5):457-470. PubMed ID: 28190245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
    Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
    Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Antihypertensive Drugs in Neoplastic Patients.
    Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
    High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma.
    Jaimes EA
    Semin Nephrol; 2020 Jan; 40(1):49-58. PubMed ID: 32130966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
    Isobe T; Komatsu R; Honda M; Kuramoto S; Shindoh H; Tabo M
    J Toxicol Sci; 2014 Apr; 39(2):237-42. PubMed ID: 24646704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinalysis by combination of the dipstick test and urine protein-creatinine ratio (UPCR) assessment can prevent unnecessary lenvatinib interruption in patients with thyroid cancer.
    Masaki C; Sugino K; Kobayashi S; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
    Int J Clin Oncol; 2020 Jul; 25(7):1278-1284. PubMed ID: 32347432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
    Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
    Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.